Fatty liver disease, now termed MASLD, is increasingly prevalent, particularly among those with weight issues, diabetes, or ...

Fat accumulation in the liver, common in both non-drinkers (NAFLD, now MASLD) and those who consume alcohol (AFLD), may ...

Certain genes may increase your risk of developing MASH. Family history may play a role in your likelihood of developing the ...

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Sagimet Biosciences (NASDAQ:SGMT) stock rises as Canaccord Genuity endorses the company's liver drug denifanstat as it launches coverage with a Buy. Read more here.

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

Many of the popular newer diabetes and weight-loss drugs are being tested to treat several additional health conditions such as liver diseases, chronic kidney ... dysfunction-associated ...

Two preclinical models for MASLD and MASH showed that vascular modifications appear at early stages of disease development even before inflammation and fibrosis.